Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database

International Clinical Psychopharmacology
Erica A VossLarry Alphs

Abstract

This report examines relapse risk following a switch from risperidone long-acting injectable (RLAI) to another long-acting injectable antipsychotic [paliperidone palmitate (PP)] versus a switch to oral antipsychotics (APs). Truven Health's MarketScan Multistate Medicaid Database compared relapses following switches from RLAI. New user cohorts for these two groups were created on the basis of first incidence of exposure to the 'switched to' drug. Groups were balanced using 1:1 propensity score matching. Time-to-event analysis assessed schizophrenia-related hospital/emergency department visits. A total of 188 patients switched from RLAI to PP, and 131 patients switched from RLAI to oral AP. Propensity score-matched cohort included 109 patients who switched to PP and 109 patients who switched to an oral AP. Patients who switched from RLAI to PP had fewer events (26 vs. 32), longer time to an event (mean 70 vs. 47 days), and lower risk of relapse (hazard ratio, 0.54; 95% confidence interval, 0.32-0.92; P=0.024) compared with those who switched from RLAI to oral AP. Switching from RLAI to PP may be associated with a lower risk for relapse and longer duration of therapy compared with switching to oral AP. Given the limitations of obs...Continue Reading

References

Jan 1, 1995·Schizophrenia Bulletin·P J Weiden, M Olfson
Sep 29, 2005·The Journal of Clinical Psychiatry·Eric Q WuJyoti Aggarwal
Feb 19, 2010·Current Medical Research and Opinion·Deborah NichollJan Schadrack
Oct 6, 2010·BMC Psychiatry·Allen W NyhuisBruce J Kinon
Jan 29, 2011·Clinical Trials : Journal of the Society for Clinical Trials·Robert A RosenheckUNKNOWN CSP 555 Research Group
Mar 4, 2011·The New England Journal of Medicine·Robert A RosenheckUNKNOWN CSP555 Research Group
Nov 1, 2011·Journal of the American Medical Informatics Association : JAMIA·J Marc OverhagePaul E Stang
Nov 21, 2012·International Clinical Psychopharmacology·Paolo Fusar-PoliRobert A Rosenheck
Feb 12, 2013·Health Services & Outcomes Research Methodology·Frank J DefalcoM Soledad Cepeda

❮ Previous
Next ❯

Citations

Dec 5, 2015·Journal of Clinical Psychopharmacology·Bunta Yoshimura, Yoshiki Kishi
Jun 2, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Christoph U CorrellJohn M Kane

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

SAS Guide
STAR

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here